Drugs / Sevasemten
Sevasemten
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06916897 | Jan → Feb 2025 | — | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05730842 | Jan → Apr 2023 | atrophic muscular disease, muscular dystrophy | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05492734 | Aug 2022 | muscular dystrophy | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05160415 | Dec 2021 → Mar 2024 | Becker muscular dystrophy | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04585464 | Oct 2020 → Nov 2021 | Becker muscular dystrophy | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06100887 | Mar 2024 → Mar 2027 expected | Duchenne muscular dystrophy | Edgewise Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06066580 | Nov 2023 → Feb 2031 expected | Becker muscular dystrophy | Edgewise Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05291091 | Nov 2022 → Sep 2026 expected | Becker muscular dystrophy | Edgewise Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05540860 | Oct 2022 → Jan 2027 expected | Duchenne muscular dystrophy | Edgewise Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sevasemten | “Sevasemten (EDG-5506) is an orally administered,” PMID 40452637 ↗ Jun 2025 |
| Known as | EDG-005506 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314486 ↗ |
| Known as | EDG-5506 | “The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker...” NCT05160415 ↗4“A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON).” NCT05291091 ↗ “Sevasemten (EDG-5506) is an orally administered,” PMID 40452637 ↗ Jun 2025 |
| Action | Inhibit | “by inhibiting fast myosin ATPase” PMID 40452637 ↗ Jun 2025 |
| Modality | Small molecule | “investigational small molecule” PMID 40452637 ↗ Jun 2025 |
| Route | Oral | “Sevasemten (EDG-5506) is an orally administered” PMID 40452637 ↗ Jun 2025 |